Company News & Publications

Upcoming Conferences

JP Morgan 35th Annual Healtcare Conference
San Francisco, CA, USA

» Visit website

JAN, 2017
09-12



Latest events

 

AAPS 2016
Denver, CO USA

» Visit website

NOV, 2016
13-17

 

 

 CPhI 2016
Barcelona, Spain

» Visit website

Oct, 2016
4-6

 

Global Congress On Prostate Cancer
Vienna, Austria

» Visit website

JuNE, 2016
29-01

 

ASCO
Chicago, IL, USA

» Visit website

may, 2016
22-25

 

TechConnect World 2016
Washington, D.D, USA

» Visit website

may, 2016
22-25

 

 

 

 

 

 

News & Press releases

 

 

DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market

19th December 2016, Swatar, Malta - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions of Celecoxib – a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). 

» Read more



 

Dr. Philip Kantoff - leading expert in clinical oncology and prostate cancer joins DRGT as Senior Clinical Advisor

14th December 2016, Malta - DRGT, a specialty pharmaceutical company announced today that Dr. Philip Kantoff joined the leadership as Senior Clinical Advisor to accelerate the progress of its ambitious oncology drug development program.

» Read more



 

DRGT’s novel Abiraterone Acetate composition – an opportunity for dose reduction and increased efficacy in prostate cancer

9th December 2016, Malta - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-45 program, a new composition of Abiraterone Acetate - a major drug in the fight against metastatic, castration-resistant prostate cancer.

» Read more



 

Quotient Clinical begins prostate cancer project for Druggability Technologies

June 23, 2015 - Quotient Clinical, the Translational Pharmaceutics® Company, initiates a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate.

» Read more



Gabor Heltovics, CEO to present at Formulation & Drug Delivery Congress, London, UK.

Join our sesseion on Day 1 , Optimising Formulation steam, 12.20 -  12.50 pm. and learn more on our latest achievments.

 

 

Druggability Technologies enters into a strategic collaboration with Bayer HealthCare

DRGT signs a broad collaboration agreement with Bayer HealthCare to leverage DRGT’s Super-API Technology to accelerate the discovery and development of novel drugs.

» Read more


Druggability Technologies Announces Financial Investment by SPCH

Druggability Technologies Holdings Limited (DRGT), a privately held biotechnology platform company, announced today that it has completed an initial round of financing totaling $4,000,000.

» Read more


Publications

Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method

Tamás Solymosi, Réka Angi, Orsolya Basa-Dénes, Soma Ránky , Zsolt Ötvös, Hristos Glavinas, Genovéva Filipcsei  and Gábor Heltovics

» Read publication

 

Novel Continuous flow technology for the development of nanostructured Aprepitant formulation with improved pharmacocinetics properties

Réka Angi, Tamás Solymosi, Zsolt Ötvös, Betti Ordasi, Hristos Glavinas, Genovéva Filipcsei, Gábor Heltovics and Ferenc Darvas

» Read publication

 

Flow chemistry for nanotechnology, Flow chemistry graduate textbook, Chapter 6, Vol.2.: Applications,  Ed. by Darvas, Ferenc / Hessel, Volker / Dorman, György, Walter de Gruyter, 2014, pp 161-187

Genovéva Filipcsei, Zsolt Ötvös, Réka Angi and Ferenc Darvas

» Read publication